Revive Therapeutics Appoints Scientific Advisor for Cannabinoid-Based Therapeutics

Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) announced the appointment of Dr. Arun Sanyal as a scientific advisor for their cannabinoid-based therapeutics targeting liver diseases.

As quoted in the press release:

“I am pleased that Dr. Sanyal has joined Revive to assist with advancing the research and clinical development of our cannabinoid-based research initiatives targeting liver diseases,” said Craig Leon, Chief Executive Officer of Revive. “Dr. Sanyal will be valuable in guiding our liver diseases product pipeline in a number of indications including liver cirrhosis, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.”

“I look forward to working with Revive Therapeutics on the broad areas of hepatic inflammation, fibrosis and cirrhosis particularly in the context of non-alcoholic fatty liver disease. I am particularly pleased to be working on the role of the cannabinoid system and non-alcoholic fatty liver disease, two areas of long standing research interest for me,” said Dr. Arun Sanyal.

Click here to read the full press release.

Get the Latest Cannabis Investing Stock Information

Get the latest information about companies associated with Cannabis Investing delivered directly to your inbox.

Cannabis

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Comments

Leave a Reply